Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients

Karel Krejci, Josef Zadrazil, Eva Lackova, Zuzana Zilinska, Robert Roland, Ivana Dedinska

Background and Aims. The CONCERTO study results showing the beneficial effects of conversion from cyclosporine to tacrolimus prolonged-release (tacrolimus PR) in stabilised patients after kidney transplantation, were first published in 2011. This communication describes our first experience of conversion from cyclosporine to tacrolimus PR in stabilised kidney transplant patients. The aim was to determine whether it could be used in routine clinical practice in the Czech and Slovak Republics.

Methods. Evaluation was carried out at five transplantation centres in the Czech Republic and Slovakia. In all participating Centres, the drug conversion was conducted according to the ICH/GCP guidelines. A total of 104 patients stabilised after kidney transplantation were converted from maintenance therapy with cyclosporine to treatment with tacrolimus PR. The data were collected 26 weeks after the switch. The primary endpoint was change in kidney graft function measured from the estimated glomerular filtration rate (GFR). The effect of conversion on blood pressure, metabolic parameters and cosmetic changes was also recorded. Special attention was paid to the safety and tolerability of treatment with tacrolimus PR.

Results. GFR increased after six months by 10% (P = 0.040). In addition a significant decrease in serum creatinine and triglycerides level was found together with major reduction in the incidence and severity of gingival hyperplasia and hirsutism. 3% of patients developed new onset of diabetes mellitus. Otherwise, the switch was very well-tolerated, without serious adverse events or acute rejections.

Conclusion. Conversion from cyclosporine to tacrolimus PR was shown to be a safe therapeutic alternative with patient benefits.

Key words: tacrolimus prolonged-release, cyclosporine, immunosuppressive conversion, kidney transplantation

INTRODUCTION

In 2011, the results of the CONCERTO study were the first published, showing the beneficial effects of conversion from cyclosporine to tacrolimus PR (brand name ADVAGRAF®) in stabilised patients after kidney transplantation. In six months of follow-up, the positive effects of conversion on kidney function and the undesirable side-events of cyclosporine treatment were observed. The study showed that kidney functions remained unchanged and the conversion to the new immunosuppressive drug was very well tolerated by patients with decrease in existing hirsutism and gingival hyperplasia. There were only minor corrections in elevated blood pressure and dyslipidaemia.

These positive results raised the interest of transplantation specialists in the Czech Republic and Slovakia and to determine whether these results could be achieved in routine clinical practice, they decided to convert their stabilised patients from immunosuppressive treatment with cyclosporine to treatment with tacrolimus PR and evaluate results of this conversion after 26 weeks. Described below are the results of this follow-up period.

MATERIALS AND METHODS

This type of research does not require approval of Institutional Review Boards or registration as a clinical trial. Evaluation was carried out at five transplantation centres in Czech Republic and Slovakia, on all participating sites the drug conversion was conducted according to the ICH/GCP guidelines. A total of 104 patients were enrolled in the project, 65 men and 39 women. The mean age was 55.0 years and mean time since the kidney transplantation was 8.3 years for the whole cohort (but for 37% of patients this period was longer than 10 years). For 92% of patients this was their first transplantation and the remaining 8% their second transplantation. No patient had more than two transplantations. Principal
demographic data are shown in Table 1. No patient interrupted treatment and hence data from all 104 patients were available.

The most common diagnoses which led to kidney failure and subsequent transplantation were chronic glomerulopathy (29%), followed by chronic interstitial nephritis or hypertensive nephrosclerosis (20%), autosomal dominant polycystic kidney disease (13%) and diabetic nephropathy (11%). The rest had kidney failure because of other causes or of unknown origin.

Prior to conversion, all 104 patients were treated with cyclosporine, in most cases in triple combination with mycophenolate and corticosteroids (67% of patients), or only in combination with mycophenolate (29%). Only one patient was treated by cyclosporine alone. 3% of patients used less the common combination of cyclosporine and azathioprin. Patients were converted from cyclosporine to tacrolimus PR, indication for conversion, conversion rate and subsequent dose of tacrolimus PR as well as frequency of outpatient controls were on physician discretion only. The mean dose of cyclosporine before conversion was 170.2 mg and mean trough blood level was 121.4 µg/ml. The mean conversion ratio from cyclosporine to tacrolimus PR was 31:1 (mg:mg), however with marked differences between centres, from the lowest ratio of 22:1 up to the highest ratio of 42:1. Mean cyclosporine dose calculated by kg of body weight was 2.21 mg/kg, mean tacrolimus PR dose calculated by kg of body weight was 0.07 mg/kg, in this case the conversion ratio was 31.6:1, i.e. about 32:1. The dosage of mycophenolate was not routinely changed after conversion. For each patient the dose depended on the clinical status and laboratory findings or on blood levels of mycophenolate and was left completely to the discretion of respective sites. Information on possible change of the dose of mycophenolate was not recorded in the follow-up file.

After the conversion to tacrolimus PR, a number of selected parameters were collected in accordance with the usual local post conversion protocol. In particular, changes in renal graft function by assessment of GFr estimated by MDRD4 equation and serum creatinine level. In addition, the effect of conversion on blood pressure, development of diabetes mellitus, parameters of lipid spectrum, changes in liver function tests and cosmetic effects were recorded. Special attention was given to the safety and tolerability of the conversion during the first six months of the follow-up.

Statistical analysis
The data were analysed using IBM SPSS Statistics for Windows, Version 20.0 (Armonk, NY: IBM Corp., USA). The data were described as means ± SD, and frequency distributions. The Chi-square test was used for categorical variables. For normative data the two-tailed t-test was used and significance level was $P < 0.05$.

RESULTS
Dose of tacrolimus PR
The mean dose of tacrolimus PR administered immediately after conversion was 5.49±2.06 mg, i.e. 0.069 mg/kg body weight. As tacrolimus belongs to drugs with narrow therapeutic index, the subsequent doses were titrated in accordance with tacrolimus levels in blood at the end of 24-hour dosing interval (trough levels). At the end of the six months follow-up period, the mean dose of tacrolimus PR was 3.66±1.96 mg, i.e. 0.046 mg/kg body weight. This decrease in dose was accompanied by similar decrease in tacrolimus blood levels, from 8.86±4.50 µg/ml at week 4 to 6.47±2.49 µg/ml at the end of the six-months period. The dynamics of decrease of both tacrolimus PR mean doses and mean tacrolimus blood levels is shown in Fig. 1. Changes in both parameters between conversion and week 26 were statistically significant.

Kidney function
The primary endpoint was the change in GFr at 26 weeks after the conversion compared to baseline. Renal function was also expressed by serum creatinine concentration. The mean level of GFr prior to conversion to tacrolimus PR was 0.79±0.39 mL/s, 26 weeks after the conversion the filtration rate increased by 0.083 mL/s to the final 0.87±0.39 mL/s, $P = 0.040$, 95% CI between -0.153 and 0.013. Mean creatinine level decreased by 17.1 µmol/l from the original value of 155.5±53.2 µmol/l at conversion to a final 138.4±50.4 µmol/l at the end of follow-up; $P = 0.0001$, 95% CI between 8.865 and 25.359.

Table 1. Principal demographic data.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Number</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>Time since transplantation (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>104</td>
<td>55</td>
<td>172</td>
<td>79</td>
<td>100</td>
</tr>
<tr>
<td>(min; max)</td>
<td>(20; 77)</td>
<td>(151; 191)</td>
<td>(44; 112)</td>
<td>(1; 304)</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>65</td>
<td>54.8</td>
<td>177</td>
<td>83</td>
<td>104</td>
</tr>
<tr>
<td>(min; max)</td>
<td>(20; 77)</td>
<td>(162; 191)</td>
<td>(64; 103)</td>
<td>(1; 304)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>39</td>
<td>55.3</td>
<td>164</td>
<td>73</td>
<td>93</td>
</tr>
<tr>
<td>(min; max)</td>
<td>(24; 72)</td>
<td>(151; 178)</td>
<td>(44; 112)</td>
<td>(1; 206)</td>
<td></td>
</tr>
</tbody>
</table>

Min, minimum; Max, maximum.
The changes in parameters corresponding to kidney function were statistically significant.

**The effect on hypertension**

At the start of follow-up, 93% of the subjects (n = 97) were assessed as being hypertensive. This remained unchanged during the whole period. However, after the 26 weeks of observation, a non-significant decrease in systolic blood pressure from 134 points of mercury to 132 points was recorded as well as a decrease in diastolic blood pressure from 81 to 77 points of mercury. There was also an important reduction of antihypertensive medication. At the beginning of the monitoring, 48% (n = 50) of patients were treated by a combination of three antihypertensives, after 26 weeks this figure dropped to 34% (n = 35). The difference was consistent with 14% of patients who were successfully switched to combination treatment with two antihypertensives only.

**Dyslipidaemia**

At the beginning of the follow-up, a clinically significant dyslipidaemia was diagnosed in 69% (n = 72) of patients. At the end of observation period the corresponding figure was 70% (n = 73). 80% of patients (n = 58) diagnosed with dyslipidaemia at any time during observation period were treated by hypolipidemic drugs. In comparison with baseline, a statistically significant decrease in mean triglyceride level was observed (P = 0.044, 95% CI between 0.007 and 0.433). Mean LDL-cholesterol level decreased insignificantly (P = 0.68; 95% CI between -0.120 and 0.182). Changes in the parameters of lipid metabolism are shown in Table 2.

**Diabetes mellitus**

Mean level of glycaemia at the start of the observation period was 5.65 mmol/L, and increased insignificantly at the end of the follow-up to 5.74 mmol/L. At the start of the monitoring, 21% of all patients (n = 22) had an already diagnosed diabetes mellitus. This subgroup was treated either by dietary regimen (in 2% of patients), by oral antidiabetics (in 5% of patients), or insulin (14% of patients). Mean daily dose of insulin did not substantially change during the 26 weeks of follow-up period, as it was 41.3 I.U. at the beginning and 41.1 I.U. at the end. After 26 weeks, the number of patients with diagnosed diabetes increased by 7% to 28% (n = 29) of the whole cohort. Some of these new patients were compensated by dietary regimen only. The number increased from 2% to a final of 8% (n = 8). The number of patients requiring insulin therapy increased as well (by 3%) and by the end of the observation represented 17% (n = 18). The level of HbA1c decreased from the original value of 5.38% to a final of 5.15%. Mean changes in the parameters of glycide metabolism are shown in Table 2.

**Hirsutism and gingival hyperplasia**

Hirsutism was recorded in 13% of patients (n = 14) treated with cyclosporine, two (2% of the total cohort) were assessed as severe. After conversion to tacrolimus PR and six months of therapy, the excessive body hair disappeared in most patients, with hirsutism seen in only 4% of patients (n = 4); all cases were mild forms. Similar development was observed with gingival hyperplasia, which before conversion afflicted 30% of all patients (n = 31), 12% of cases (n = 12) were diagnosed as severe. After six months of treatment gingival hyperplasia generally retreated and persisted in only 2% (n = 2) of patients in a mild form.

**Other evaluated parameters**

At both the beginning and the end of observation, BMI, pulse frequency and other vital functions were recorded in all patients. Blood samples were taken and levels of selected biochemical parameters - ALT, AST, bilirubin - were assessed to evaluate potential hepatotoxicity. During the follow-up period no major change in any

**Table 2.** Parameters of lipid and glycide metabolism before and after conversion.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>LDL cholesterol (mmol/L)</th>
<th>Triglycerides (mmol/L)</th>
<th>Glycemia (mmol/L)</th>
<th>HbA1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mean±SD</td>
<td>mean±SD</td>
<td>mean±SD</td>
<td>mean±SD</td>
</tr>
<tr>
<td>Before conversion</td>
<td>2.48±0.74</td>
<td>2.90±1.64</td>
<td>5.65±1.32</td>
<td>5.38±2.43</td>
</tr>
<tr>
<td>After 26 weeks</td>
<td>2.29±0.65</td>
<td>1.79±1.23</td>
<td>5.74±1.17</td>
<td>5.15±1.55</td>
</tr>
<tr>
<td>Statistical significance</td>
<td>n.s.</td>
<td>0.044</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

Data are mean ± standard deviation (SD). LDL, low density lipoprotein; HbA1c, glycated haemoglobin.
of these parameters was recorded. The mean results of clinical and biochemical records are shown in Table 3.

### Safety and tolerance

During the 26 weeks of follow-up, no case of subject discontinuation for lack of efficacy or adverse event was recorded. All patients finished six months follow-up on tacrolimus PR and continued to be treated further. No investigator reported any unexpected drug reaction or drug related adverse event. Patients tolerated the treatment with tacrolimus PR well. In 7% of patients, new onset of diabetes was recorded but 5% of these were compensated by diet regimen only.

#### Assessment of the treatment by physicians

At the end of 26-week follow-up, the physicians were asked to categorise individual patients as improved, unchanged or worse. If the patient was worse, the reason was investigated. This assessment was done twice, from the efficacy as well as from the safety and tolerance point of view. In the efficacy assessment, 56% of patients (n = 58) were evaluated as improved, 38% patients (n = 40) showed no substantial change and in 6% of cases (n = 6) the status was described as worse. In all six cases, the cause was the slow decline in renal function and gradual deterioration of the graft. These cases of deterioration were perceived by investigators to be caused by the age of the graft (i.e. long time after transplantation) and/or patient comorbidities. In no case was the reason for worse efficacy outcome linked to the conversion to tacrolimus PR. No sudden impairment in kidney graft function which could be linked to the acute rejection was recorded during the 26-weeks follow-up. There was also no case of graft loss during this period. Improved tolerance of the treatment after conversion was recorded in 48% of patients, 46% of patients remained without substantial change and in 6% of cases a worse tolerance to treatment mainly due to mild form of tremor and diarrhoea was recorded.

### DISCUSSION

The results of this follow-up in routine clinical conditions confirmed the results of the clinical study CONCERTO, namely efficacy and tolerance of conversion from cyclosporine to tacrolimus PR. The switch to a new immunosuppressive therapy went smoothly, without any acute rejection or any significant adverse event linked to the treatment.

### Table 3. Selected clinical and biochemical parameters before and after conversion.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>BMI</th>
<th>Pulse frequency (min) mean±SD</th>
<th>ALT (µkat/L) mean±SD</th>
<th>AST (µkat/L) mean±SD</th>
<th>Bilirubin (mmol/L) mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before conversion</td>
<td>26.8±4.5</td>
<td>74±7.0</td>
<td>0.42±0.19</td>
<td>0.42±0.18</td>
<td>10.82±5.50</td>
</tr>
<tr>
<td>After 26 weeks</td>
<td>26.9±4.6</td>
<td>73±7.0</td>
<td>0.40±0.19</td>
<td>0.39±0.14</td>
<td>11.11±8.29</td>
</tr>
<tr>
<td>Statistical significance</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

Data are means ± standard deviation (SD). BMI, Body Mass Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
CONCLUSION

Conversion from cyclosporine to tacrolimus PR went smoothly in stabilised patients who were treated by cyclosporine for many years following kidney transplantation. The mean kidney functions improved as well as other clinical and laboratory parameters such as decrease in the use of antihypertensive medication, diastolic blood pressure and triglyceride blood levels. The so-called cosmetic side effects of cyclosporine (hirsutism, gingival hyperplasia) nearly disappeared. Most of the results of our observational project performed in routine clinical conditions confirmed the results of the CONCERTO study. Surprising was the observed improvement in GFR and decrease in serum creatinine levels.

ABBREVIATIONS

Tacrolimus PR, tacrolimus prolonged-release; ICH/GCP, International Council for Harmonisation/Good Clinical Practice; GFR, glomerular filtration rate; MDRD4, 4-variable Modification of Diet in Renal Disease; SD, standard deviation; CI, confidence interval; LDL, low density lipoprotein; I.U., International Unit; HbA1c, glycated haemoglobin; BMI, Body Mass Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Author contributions: All authors contributed equally to preparing the manuscript.
Conflict of interest statement: None declared.

REFERENCE